Device Trial Radar · NCT03332238
Stromal Vascular Fraction Cell Therapy to Improve the Repair of Rotator Cuff Tears
Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
56
Planned (sponsor's estimate)
Start
Jul 1, 2019
Primary completion
Dec 31, 2026
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Hospital for Special Surgery, New YorkAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Orthopedic Research and Education Foundation
- First posted
- Nov 6, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 45 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Rotator cuff disease is one of the most prevalent musculoskeletal conditions across the world. Patients with chronic rotator cuff tears often have substantial muscle atrophy and fatty infiltration. Surgical repair of the tear does not reverse the atrophy, and many patients continue to experience weakness, pain, and a persistent reduction in the quality of life. An important limitation in our ability to successfully rehabilitate these injuries postoperatively and return patients to normal function has to do with the poor quality of the muscle and tendon after rotator cuff repair. The stromal vascular fraction (SVF) of subcutaneous adipose tissue is highly enriched with cells (SVFCs) that can both directly participate in tissue regeneration by differentiating into myogenic and tenogenic cells, and indirectly by secreting growth factors and small molecules which activate pathways associated with healthy tissue regeneration. High numbers of autologous SVFCs can be isolated using the cost-effective, intraoperative Icellator (Tissue Genesis, Honolulu, HI) point-of-care system. This clinical trial will be determine if the use of SVFCs can enhance outcomes for patients who are undergoing surgical repair of a torn supraspinatus rotator cuff.
Conditions
- Rotator Cuff Tear
- Muscle Atrophy
- Tendon Tear
Interventions
Autologous Stomal Vascular Fraction MaterialDevice
Autologous Stomal Vascular Fraction Material Prepared from the Tissue Genesis® Icellator Cell Isolation System™
Ringer's solutionDevice
Ringer's solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in scapular plane abduction strength from baseline, and additional isometric, isokinetic strength measurements to assess supraspinatus function.Time frame: 2 weeks prior to surgery, 6 months after surgery, 12 months after surgery, 24 months after surgery
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hospital for Special Surgery
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.